IPAP Study
Research type
Research Study
Full title
Investigation to determine the utility of novel biomarkers in Patients with Peripheral arterial disease
IRAS ID
161776
Contact name
Gina Sanki
Contact email
Sponsor organisation
Cwm Taf UHB
Duration of Study in the UK
4 years, 11 months, 30 days
Research summary
Early diagnosis or identification of those at risk of developing peripheral artery disease (PAD) could improve outcomes for patients, as prevention of PAD through earlier treatment of those at risk would offer patient benefit and reduce the burden on the NHS.
It is estimated that in the UK, 1 in 5 people aged over 60 years have some degree of PAD. Furthermore in those with PAD only 40% will experience symptoms, and then only a third of those who do experience symptoms report them to their doctor. Often the symptoms are seen by the PAD sufferers as natural aging. This suggests that symptom less people would be missed using the screening questionnaire currently in use, which relies on people recognizing the painful symptoms of peripheral arterial disease.
The principal objective of this study is to determine the levels of targeted blood borne biomarkers in participants newly diagnosed with PAD. These will be measured in parallel with physiological and cardiovascular parameters which are required to assess the severity of PAD.
Blood borne markers which are shown to be present in the blood of participants with peripheral arterial disease at a significant level will be used in a future study to help develop a risk score for early identification of patients at risk of peripheral arterial disease in general practice (primary care). The development of the risk score will form a separate ethics application.REC name
Wales REC 2
REC reference
15/WA/0031
Date of REC Opinion
19 Mar 2015
REC opinion
Further Information Favourable Opinion